This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Suzhou Ribo Life Science Company, Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Liqiang Cao: Innovator in Oligonucleotide Delivery Systems
Introduction
Liqiang Cao is a prominent inventor based in Kunshan, China. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that enhance the delivery of oligonucleotide drugs. His innovative work addresses critical challenges in drug delivery systems, making him a notable figure in his industry.
Latest Patents
Liqiang Cao holds a patent for "Conjugates and preparation and use thereof." This patent describes a compound designed to form a conjugate with an active agent, such as an oligonucleotide, represented by a specific structural formula. The conjugate developed by Cao can specifically target hepatocytes, effectively solving the issues associated with the in vivo delivery of oligonucleotide drugs. This innovation boasts low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.
Career Highlights
Cao is currently employed at Suzhou Ribo Life Science Company, Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key player in the biotechnology sector, particularly in the area of drug delivery systems.
Collaborations
Liqiang Cao collaborates with notable colleagues, including Hongyan Zhang and Zhiwei Yang. Their combined expertise contributes to the innovative projects at Suzhou Ribo Life Science Company, Ltd.
Conclusion
Liqiang Cao's contributions to the field of oligonucleotide delivery systems highlight his role as an influential inventor. His innovative approaches are paving the way for advancements in drug delivery technologies, ultimately benefiting the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile